FDA advisers give thumbs-down to Alzheimer’s drug, saying it lacks efficacy data.

An experimental Alzheimer’s disease drug described by FDA staff as safe and effective stumbled badly when an agency advisory committee said there was not sufficient evidence to conclude the drug is effective. The non-binding action raised questions about whether the FDA would approve the drug.

View original article
Contributor: Laurie McGinley